Related Experiment Video

Updated: Aug 6, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

[Chronic heart failure treatment in uremic patients with beta-blockers]

G Cice1, S D'Isa

  • 1Cattedra di Cardiologia, Seconda Università degli Studi di Napoli, Napoli-Italy. gennarocice@hotmail.com

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|July 27, 2006
PubMed

Insights

Congestive heart failure (CHF) treatment evolved from hemodynamics to neurohumoral targets. Betablockers, like carvedilol, show efficacy in dialysis patients, improving outcomes and mortality.

Area of Science:

  • Cardiology and Nephrology
  • Pharmacology and Therapeutics

Context:

  • Congestive heart failure (CHF) interpretation shifted from hemodynamic to neurohumoral mechanisms in the 1980s.
  • Neurohumoral activation is a key factor in CHF worsening and poor prognosis, leading to the use of ACE inhibitors, beta-blockers, and ARBs.
  • Evidence for these treatments primarily comes from studies on the general population, with limited dedicated trials in uremic patients.

Purpose:

  • To evaluate the efficacy of treatments for congestive heart failure (CHF) in uremic patients, specifically those on dialysis.
  • To determine if treatment rationales and outcomes observed in the general CHF population are applicable to uremic individuals.

Summary:

  • Cardiovascular drugs initially focused on hemodynamics with limited success.
  • Neurohumoral targets became central, with ACE inhibitors, beta-blockers, and ARBs showing promise in reducing morbidity and mortality in general CHF populations.
  • A randomized trial demonstrated carvedilol's effectiveness in the dialysis population, improving left ventricular function and reducing hospitalization, cardiovascular deaths, and total mortality.

Impact:

  • Highlights the potential for similar therapeutic strategies and outcomes in uremic and non-uremic CHF patients.
  • Supports the use of beta-blockers, specifically carvedilol, as an effective treatment for CHF in dialysis patients.
  • Underscores the need for further research into CHF management tailored for uremic populations.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...